857 reports of this reaction
1.4% of all ANAKINRA reports
#15 most reported adverse reaction
DRUG HYPERSENSITIVITY is the #15 most commonly reported adverse reaction for ANAKINRA, manufactured by Swedish Orphan Biovitrum AB (publ). There are 857 FDA adverse event reports linking ANAKINRA to DRUG HYPERSENSITIVITY. This represents approximately 1.4% of all 60,861 adverse event reports for this drug.
Patients taking ANAKINRA who experience drug hypersensitivity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG HYPERSENSITIVITY is a less commonly reported adverse event for ANAKINRA, but still significant enough to appear in the safety profile.
In addition to drug hypersensitivity, the following adverse reactions have been reported for ANAKINRA:
The following drugs have also been linked to drug hypersensitivity in FDA adverse event reports:
DRUG HYPERSENSITIVITY has been reported as an adverse event in 857 FDA reports for ANAKINRA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG HYPERSENSITIVITY accounts for approximately 1.4% of all adverse event reports for ANAKINRA, making it a notable side effect.
If you experience drug hypersensitivity while taking ANAKINRA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.